EN 简
search
EN 简

Press Release

ASGCT 2026 | JW Therapeutics Presents Preclinical Data of JWCAR201 and JWCAR239 at the 29th Annual Meeting of the American Society of Gene & Cell Therapy
09 May, 2026
JW Therapeutics' Relma-cel IIT Study in Systemic Sclerosis (SSc) Selected as Late-Breaking Abstract at the Systemic Sclerosis World Congress (SSWC)
05 March, 2026
JW Therapeutics Presents JWCAR201 IIT Study Data at the 67th American Society of Hematology Annual Meeting
08 December, 2025
JW Therapeutics' Carteyva® Successfully Included in the First Edition of the National Healthcare Security Administration's Commercial Health Insurance Innovative Drug Directory
07 December, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development
30 October, 2025
JW Therapeutics Submitted data from the Phase I study of Relma-cel in Chinese adult patients with active systemic lupus erythematosus to China National Medical Products Administration
21 October, 2025
National Medical Products Administration has officially accepted the post-marketing supplemental application for Carteyva®, which uses an in-house produced lentiviral vector
09 October, 2025
JW Therapeutics Completes First Patient Infusion in Clinical Study of JWCAR239 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
26 September, 2025
JW Therapeutics Announces Approval of Carteyva® (Relmacabtagene Autoleucel Injection) for Marketing in Macao
04 June, 2025
NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA® AS SECOND-LINE TREATMENT IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
28 May, 2025
Next Generation MAGE-A4 TCR-T cell program in China
29 April, 2025
JW Therapeutics Announces sLVV License Agreement with Juno Therapeutics
23 April, 2025
Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
10 January, 2025